Mydecine Innovations Group

Watch this video to learn how we're developing improved second-generation drugs with @api_applied at the @UAlberta to treat mental health and addiction disorders. Full video here: youtu.be/R2vWc18gubU ​​$MYCO.NE $MYCOF $ONFA.F

We've filed our full patent application covering our MYCO-006 family of novel short-acting MDMA analogs! Full story here: bit.ly/3RIIX4B ​​$MYCO.NE $MYCOF #Psychedelics

We're excited to share that the FDA has cleared MYCO-001 in a recent IND application, marking the first clearance of our drug product! Get the full scoop: bit.ly/3mUo1cH ​​$MYCO.NE $MYCOF

Today we released an update on our clinical trial and drug development initiatives and welcomed a new member to our board of directors! Full release here:bit.ly/3H7LPmC $MYCO.NE $MYCOF

Created by @WHO in 1987, #worldnotobaccoday aims to draw attention to the tobacco epidemic. Tobacco growing, manufacturing & use poison our water, soil, beaches & city streets with chemicals, toxic waste, and cigarette butts. Learn how to make a difference:bit.ly/3alUhlW

At Mydecine, we have a global team with 100s of years of experience in medicinal chemistry & pharmaceutical drug development, an end-to-end drug development infrastructure under one roof, and a growing library of novel #psychedelic molecules. Learn more: bit.ly/39P7fsm

Europe’s 1st commercial facility for psychedelic drug trials is to open in London! We've started working with @clerkenwell_uk to lay the groundwork for future clinical trials in the UK. Full article: bit.ly/3yoGipv

.It's been over 70 years since the first observations of PTSD were recorded, and yet there still aren't many great treatment options widely available. The time for new treatments is now!

MYCO-004 is a short-acting, skin-permeable, patch-delivered #tryptamine compound that has a faster onset time with reduced side effects compared to classic #psilocybin. These features enable better integration into our existing #healthcare infrastructure. bit.ly/3hGBDWy

We are proud to be a sponsor of this study at @Macquarie_Uni, led by Mydecine Advisory Board member Dr. Vince Polito, assessing psilocybin as an antidepressant. According to @WHO, roughly 280 million people globally suffer from depression. Learn more: bit.ly/3vkd9cZ

.If you missed CEO Josh Bartch's presentation at the Sequire Cannabis and Psychedelics Conference, you can click the link below to catch the replay!

The first Earth Day took place on April 22, 1970. Today we celebrate 52 years of #EarthDay! Learn more: epa.gov/earthday

Psilocybin has the ability to increase neuroplasticity, the brain's ability to change through growth & reorganization of its neural networks, giving patients an opportunity to treat their raw addiction rather than just treating their symptoms. bit.ly/3uXoeAR @TIME

Great read by @MarcGunther touching on the behind-the-scenes aspects of funding psychedelic research and @Drug_Researcher's groundbreaking work in this field! @lucidnewssite $MYCO.NE $MYCOF #MedicineEvolved #psychedelicscience Full Story: bit.ly/3LY7FtU

Today we celebrate #WorldHealthDay & reiterate our commitment to promoting health & well-being by creating new therapies for patients. Let’s keep pushing forward to remove stigmas around #mentalhealth & create safe, evidence-based medicines for a #HealthierTomorrow!

In the 1st year of the COVID-19 pandemic, the prevalence of anxiety and depression worldwide increased by 25%, according to a WHO brief released earlier this month (bit.ly/378Lwu8). Learn how we're developing innovative treatments to address this by visiting our website.

Join CEO Josh Bartch at the Sequire Cannabis & Psychedelic Conference on April 20th at 11 am ET to learn more about Mydecine and what's in store for 2022! Register or learn more here: cannabis-conference22.mysequ… @SRAXmedia